How to Evaluate Perfusion Imaging in Post-treatment Glioma: a Comparison of Three Different Analysis Methods

Overview

Journal Neuroradiology

Specialties Neurology
Radiology

Date 2024 May 7

PMID 38714545

Authors

Siem D A Herings

Rik van den Elshout

Rebecca de Wit

Manoj Mannil

Cecile Ravesloot

Tom W J Scheenen

Anne Arens

Anja van der Kolk

Frederick J A Meijer

Dylan J H A Henssen

Affiliations

Soon will be listed here.

Abstract

Introduction: Dynamic susceptibility contrast (DSC) perfusion weighted (PW)-MRI can aid in differentiating treatment related abnormalities (TRA) from tumor progression (TP) in post-treatment glioma patients. Common methods, like the 'hot spot', or visual approach suffer from oversimplification and subjectivity. Using perfusion of the complete lesion potentially offers an objective and accurate alternative. This study aims to compare the diagnostic value and assess the subjectivity of these techniques.

Methods: 50 Glioma patients with enhancing lesions post-surgery and chemo-radiotherapy were retrospectively included. Outcome was determined by clinical/radiological follow-up or biopsy. Imaging analysis used the 'hot spot', volume of interest (VOI) and visual approach. Diagnostic accuracy was compared using receiving operator characteristics (ROC) curves for the VOI and 'hot spot' approach, visual assessment was analysed with contingency tables. Inter-operator agreement was determined with Cohens kappa and intra-class coefficient (ICC).

Results: 29 Patients suffered from TP, 21 had TRA. The visual assessment showed poor to substantial inter-operator agreement (κ = -0.72 - 0.68). Reliability of the 'hot spot' placement was excellent (ICC = 0.89), while reference placement was variable (ICC = 0.54). The area under the ROC (AUROC) of the mean- and maximum relative cerebral blood volume (rCBV) (VOI-analysis) were 0.82 and 0.72, while the rCBV-ratio ('hot spot' analysis) was 0.69. The VOI-analysis had a more balanced sensitivity and specificity compared to visual assessment.

Conclusions: VOI analysis of DSC PW-MRI data holds greater diagnostic accuracy in single-moment differentiation of TP and TRA than 'hot spot' or visual analysis. This study underlines the subjectivity of visual placement and assessment.

References

Zikou A, Sioka C, Alexiou G, Fotopoulos A, Voulgaris S, Argyropoulou M . Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. Contrast Media Mol Imaging. 2019; 2018:6828396. PMC: 6305027. DOI: 10.1155/2018/6828396. View

Wen P, Macdonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28(11):1963-72. DOI: 10.1200/JCO.2009.26.3541. View

Young R, Gupta A, Shah A, Graber J, Zhang Z, Shi W . Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology. 2011; 76(22):1918-24. PMC: 3115805. DOI: 10.1212/WNL.0b013e31821d74e7. View

Thust S, Heiland S, Falini A, Jager H, Waldman A, Sundgren P . Glioma imaging in Europe: A survey of 220 centres and recommendations for best clinical practice. Eur Radiol. 2018; 28(8):3306-3317. PMC: 6028837. DOI: 10.1007/s00330-018-5314-5. View

Jahng G, Li K, Ostergaard L, Calamante F . Perfusion magnetic resonance imaging: a comprehensive update on principles and techniques. Korean J Radiol. 2014; 15(5):554-77. PMC: 4170157. DOI: 10.3348/kjr.2014.15.5.554. View

Smits M . MRI biomarkers in neuro-oncology. Nat Rev Neurol. 2021; 17(8):486-500. DOI: 10.1038/s41582-021-00510-y. View

Wintermark M, Sesay M, Barbier E, Borbely K, Dillon W, Eastwood J . Comparative overview of brain perfusion imaging techniques. J Neuroradiol. 2006; 32(5):294-314. DOI: 10.1016/s0150-9861(05)83159-1. View

Wang L, Wei L, Wang J, Li N, Gao Y, Ma H . Evaluation of perfusion MRI value for tumor progression assessment after glioma radiotherapy: A systematic review and meta-analysis. Medicine (Baltimore). 2020; 99(52):e23766. PMC: 7769293. DOI: 10.1097/MD.0000000000023766. View

van Dijken B, van Laar P, Holtman G, van der Hoorn A . Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis. Eur Radiol. 2017; 27(10):4129-4144. PMC: 5579204. DOI: 10.1007/s00330-017-4789-9. View

10.

Patel P, Baradaran H, Delgado D, Askin G, Christos P, Tsiouris A . MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. Neuro Oncol. 2016; 19(1):118-127. PMC: 5193025. DOI: 10.1093/neuonc/now148. View

11.

Manfrini E, Smits M, Thust S, Geiger S, Bendella Z, Petr J . From research to clinical practice: a European neuroradiological survey on quantitative advanced MRI implementation. Eur Radiol. 2021; 31(8):6334-6341. PMC: 8270851. DOI: 10.1007/s00330-020-07582-2. View

12.

Welker K, Boxerman J, Kalnin A, Kaufmann T, Shiroishi M, Wintermark M . ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain. AJNR Am J Neuroradiol. 2015; 36(6):E41-51. PMC: 5074767. DOI: 10.3174/ajnr.A4341. View

13.

Boxerman J, Quarles C, Hu L, Erickson B, Gerstner E, Smits M . Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro Oncol. 2020; 22(9):1262-1275. PMC: 7523451. DOI: 10.1093/neuonc/noaa141. View

14.

Alsop D, Detre J, Golay X, Gunther M, Hendrikse J, Hernandez-Garcia L . Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med. 2014; 73(1):102-16. PMC: 4190138. DOI: 10.1002/mrm.25197. View

15.

Schmainda K, Prah M, Hu L, Quarles C, Semmineh N, Rand S . Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors. AJNR Am J Neuroradiol. 2019; 40(4):626-633. PMC: 6461489. DOI: 10.3174/ajnr.A6015. View

16.

Smits M, Bendszus M, Collette S, Postma L, Dhermain F, Hagenbeek R . Repeatability and reproducibility of relative cerebral blood volume measurement of recurrent glioma in a multicentre trial setting. Eur J Cancer. 2019; 114:89-96. DOI: 10.1016/j.ejca.2019.03.007. View

17.

Oei M, Meijer F, Mordang J, Smit E, Idema A, Goraj B . Observer variability of reference tissue selection for relativecerebral blood volume measurements in glioma patients. Eur Radiol. 2018; 28(9):3902-3911. PMC: 6096614. DOI: 10.1007/s00330-018-5353-y. View

18.

Hu L, Eschbacher J, Heiserman J, Dueck A, Shapiro W, Liu S . Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro Oncol. 2012; 14(7):919-30. PMC: 3379799. DOI: 10.1093/neuonc/nos112. View

19.

Prah M, Al-Gizawiy M, Mueller W, Cochran E, Hoffmann R, Connelly J . Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics. J Neurooncol. 2017; 136(1):13-21. PMC: 5756123. DOI: 10.1007/s11060-017-2617-3. View

20.

Kuo F, Ng N, Nagpal S, Pollom E, Soltys S, Hayden-Gephart M . DSC Perfusion MRI-Derived Fractional Tumor Burden and Relative CBV Differentiate Tumor Progression and Radiation Necrosis in Brain Metastases Treated with Stereotactic Radiosurgery. AJNR Am J Neuroradiol. 2022; 43(5):689-695. PMC: 9089266. DOI: 10.3174/ajnr.A7501. View